News2 – Verséa
 

News2

Verséa Discovery, Inc. Announces the Official Launch of mescreen™ Research Validator – a Revolutionary Mitochondrial Compound Assessment Platform

8/27/2024, Tampa, FL – Verséa Discovery, Inc., a Florida-based company dedicated to advancing scientific research and development in the area of personalized and precision medicine, has announced the official launch of mescreen™ Research Validator. The mescreen™ Research Validator is a groundbreaking, proprietary compound assessment platform that harnesses mitochondrial function and dynamics to generate critical data,...

Verséa Health, Inc. Announces the Official Launch of Empowered Choice™  – An Affordable and Accessible Emergency Contraceptive

8/22/2024, Tampa, FL – Verséa Health, Inc. (“Verséa”), a Florida-based transformative healthcare company specializing in the commercialization of innovative diagnostics, therapeutics, and health services, has officially launched Empowered Choice™, a safe and effective over-the-counter emergency contraceptive. Empowered Choice™ is an FDA approved, 1.5 mg Levonorgestrel tablet that provides the same proven effective emergency contraception as...

Verséa Health, Inc. Announces the Official Launch of Party Safe™ Fentanyl ID Test – A Convenient and Accurate Solution for Fentanyl Detection On-the-Go

8/21/2024, Tampa, FL – Verséa Health, Inc. (“Verséa”), a Florida-based transformative healthcare company specializing in the commercialization of innovative diagnostics, therapeutics, and health services, has officially launched Party Safe™ Fentanyl ID Test. Manufactured by a leading US supplier to law enforcement and healthcare providers, Party Safe™ Fentanyl ID Test is a dependable over-the-counter product, featuring...

Verséa Health, Inc. Acquires ISO 9001 Certification

TAMPA, FL., June 6, 2024 — Verséa Health, Inc. (“Verséa”), a Florida-based transformative health care company specializing in the commercialization of innovative diagnostics, therapeutics, and health services, has successfully acquired the ISO 9001 certification. Securing ISO 9001 certification across all three Verséa Health’s strategic business units – Diagnostics, Ophthalmics, and Discovery – represents a substantial accomplishment....

WEST POINT OPTICAL GROUP, LLC AND VERSÉA OPHTHALMICS, INC. ANNOUNCE PARTNERSHIP SUPPLY AGREEMENT FOR  BIOVANCE®AND BIOVANCE® 3L OCULAR

MASON, OH and TAMPA, FL., April 3, 2024 — West Point Optical Group, LLC (“WPOG”), providing quality patient care by developing experienced, well-rounded vision health teams within its 86 Pearle Vision stores, and Verséa Ophthalmics, Inc. (“Verséa Ophthalmics”), a Tampa, FL-based company that focuses on providing complete ocular point-of-care diagnostic and therapeutic interventions, today announced...

Verséa Ophthalmics and Celularity Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3L Ocular for Ophthalmic Applications

TAMPA, FL. and FLORHAM PARK, N.J., July 27, 2023 — Verséa Ophthalmics, LLC (“Verséa Ophthalmics”), a Tampa, FL-based company that focuses on providing complete ocular point-of-care diagnostic and therapeutic interventions, and Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that the companies have entered into...

Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform

7/25/2022, Tampa, FL – Verséa™ Ophthalmics, LLC, a division of Verséa Health, Inc. committed to delivering novel, high-value diagnostic and therapeutic solutions to improve ocular disease, proudly announces the commencement of initial shipments of its T-POC TOTAL IgE Immunoassay and Lateral Flow  Readers. The company focuses on delivering innovative Tear-based Point-of-Care (T-POC) testing and biologic solutions that...

Verséa Health and iRemedy Announce Strategic Joint Venture

Tampa, FL – June 28, 2023 – Verséa Health, Inc., a prominent provider of diagnostics and medical supplies for urgent care centers, and iRemedy Healthcare Companies, Inc. (“iRemedy”), a trailblazer in the medical supply e-commerce industry, are thrilled to announce their strategic joint venture. The collaboration aims to establish an integrated ecosystem of services tailored...

Verséa Health and Doc Johnson to Launch Wellness Center for Retailers

Tampa, FL. — Verséa Health, Inc. has partnered with Doc Johnson to launch a new Doc Johnson Wellness Center display available to retailers. This exclusive new partnership will provide Doc Johnson customers with access to cutting-edge diagnostics, treatments and preventive care services that are tailored to their individual needs. The Doc Johnson Wellness Center will include...